SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

Millennium Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

599902 10 3 (CUSIP Number)

Check the following box if a fee is being paid with the statement ($\)$ $\$ (A fee is not required only if

the reporting person: (1) has a previous statement on file reporting beneficial ownership of more than five percent of the class of securities described in Item 1; and (2) has filed no amendment subsequent thereto reporting beneficial ownership of five percent or less of such class.) (See Rule 13d-7).

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Page 1 of 5 Pages

CUSIP No. 599902 10 3

- (1) Name of Reporting Person: Eli Lilly and Company
 S.S. or I.R.S. Identification 35-0470950
 No. of Above Person
- (2) Check the Appropriate Box (a)if a Member of a Group (b)

(a) () ---(b) () ---Not Applicable

(3) SEC Use Only

(4)Citizenship or Place of Indiana Organization Number of Shares (5) Sole Voting 1,358,333 Beneficially Owned Power by Each Reporting (6) Shared Voting None Person With Power (7) Sole Dispositive 1,358,333 Power (8) Shared Disposi-None tive Power

Owned by Each Reporting Person

(10)	Check if the Aggregate Amount
	In Row (9) Excludes Certain Shares

- (11) Percent of Class Represented
 by Amount in Row (9)
- (12) Type of Reporting Person
- Not Applicable 5.7% at December 31, 1996

CO

Item 1(a).	Name of Issuer
	Millennium Pharmaceuticals, Inc.
Item 1(b).	Address of Issuer's Principal Executive Offices
	640 Memorial Drive Cambridge, MA 02139
Item 2(a).	Name of Person Filing
	Eli Lilly and Company
Item 2(b).	Address of Principal Business Office or, if None, Residence
	Lilly Corporate Center Indianapolis, IN 46285
Item 2(c).	Citizenship
	Indiana
Item 2(d).	Title of Class of Securities
	Common Stock
Item 2(e).	CUSIP No.
	599902 10 3
Item 3.	Status of Filer Under Rules 13d-1(b) or 13d-2(b)
	Not applicable

Item 4.	Owner	Dwnership		
	(a)	Amount Beneficially Owr	ned	
		1,358,333		
	(b)	Percent of Class		
		5.7% as of December 31,	1996	
	(c)	Voting and Dispositive Power		
		Sole voting power	1,358,333	
		Shared voting power	None	
		Sole dispositive power	1,358,333	
		Shared dispositive powe	er None	
Item 5.	Ownership of F	nership of Five Percent or Less of a Class		
	Not Applicable			
Item 6.	Ownership of More Than Five Percent on Behalf of Another Person			
	Not applicable			
Item 7.	Subsidiary which	entification and Classification of the bsidiary which Acquired the Security ing Reported on by the Parent Holding mpany		
	Not applicable			
Item 8.	Identification Members of the	and Classification of Group		
	Not applicable			
Item 9.	Notice of Disso	olution of Group		
	Not applicable			
Item 10.	Certification			
	Not applicable			

Page 4 of 5 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

ELI LILLY AND COMPANY

BY:

Edwin W. Miller Vice President and Treasurer

Date: February 11, 1997

Page 5 of 5 Pages